ArticleInflammopharmacology2026
Heightened anti-inflammatory and antioxidant effects of bone marrow stem cell-conditioned media with mono and doped TiO
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bio inspired assessment of titanium-organic framework and exosome-constructed p-Synephrine carriage: pursuing the PI3K/mTOR pathway in a simulated periodontitis.Scientific reports · 2026Article
- Healing the unhealable: Wharton's jelly stem cell vesicles as a breakthrough for feline chronic skin ulcers.Irish veterinary journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation and oxidative stress are key mediators of tissue damage in numerous pathological conditions. This study investigated the anti-inflammatory and antioxidant effects of titanium dioxide nanoparticles (TiO₂ NPs), mono-doped TiO₂ (Cu), and dual-doped TiO₂ (Cu/Zn) in a carrageenan-induced paw edema model. TiO₂ nanoparticles were synthesized and characterized by XRD, SEM, TEM, DLS, and EDX, confirming an anatase crystalline phase, spherical morphology, and uniform size distribution with successful dopant incorporation. Bone marrow mesenchymal stem cells (BM-MSCs) were isolated and characterized by flow cytometry (CD90⁺, CD73⁺, CD34⁻, CD45⁻) and trilineage differentiation, and their conditioned media (CM) were used for therapeutic application. A pre-study screening using three doses (10, 20, and 50 mg/kg) demonstrated a dose-dependent reduction in paw edema, with the 50 mg/kg dose showing the highest inhibition, comparable to indomethacin. The main experiment comprised six groups: control, carrageenan, indomethacin, TiO₂ CM, Cu-TiO₂ CM, and Cu/Zn-TiO₂ CM. Carrageenan administration elevated TNF-α, IL-6, IL-4, COX-2, and 5-LOP while reducing IL-10, alongside increased oxidative stress markers (MDA and NO) and decreased antioxidant defenses (CAT, SOD, GPx, and TAC). Treatment with TiO₂ formulations markedly reversed these effects in a dose-dependent manner. Dual-doped TiO₂ combined with BM-MSC-CM produced the greatest improvement, normalizing cytokine profiles, reducing lipid peroxidation and nitric oxide levels, and restoring antioxidant enzyme activities. Histopathological assessment confirmed these findings, showing nearly normal dermal architecture with minimal inflammatory infiltration. The results highlight the synergistic therapeutic potential of doped TiO₂ nanoparticles and BM-MSC-CM in mitigating inflammation and oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.